Irinotecano Accord

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecano Accord, is a topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and advanced colorectal cancer in adult patients.

GNH USA supplies Irinotecano Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecano Accord is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

Metastatic colorectal cancer: improves survival when combined with standard chemotherapy regimens. Colorectal cancer (advanced): reduces tumor burden and disease progression. Colorectal cancer (first‑line): administered with fluorouracil and leucovorin as part of a standard combination protocol.

Irinotecano Accord may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe, may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: generalized tiredness during treatment cycles. - Alopecia: hair loss that is usually reversible.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: intense abdominal pain and bloody diarrhea. - Cholinergic syndrome: abdominal cramps, sweating, and bradycardia. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors.

Monitor blood counts: perform complete blood count before each infusion. Assess liver function: adjust dosing if bilirubin or transaminases are elevated. Hydration: ensure adequate fluid intake to mitigate severe diarrhea. Avoid concurrent strong CYP3A4 inhibitors: may increase irinotecan exposure. Pregnancy: contraindicated unless potential benefit justifies risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecano Accord can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels. - UGT1A1 inhibitors (e.g., atazanavir): increase risk of toxicity. - Concurrent myelosuppressive agents: amplify bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticholinergic drugs: may exacerbate cholinergic syndrome. - Anticoagulants: monitor for altered bleeding risk.